A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment

Hegde, 2020, Top 10 challenges in cancer immunotherapy, Immunity, 52, 17, 10.1016/j.immuni.2019.12.011 van den Bulk, 2018, Cancer immunotherapy: broadening the scope of targetable tumours, Open Biol, 8, 10.1098/rsob.180037 Yang, 2015, Cancer immunotherapy: harnessing the immune system to battle cancer, J Clin Invest, 125, 3335, 10.1172/JCI83871 Emens, 2017, Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape, Eur J Cancer, 81, 116, 10.1016/j.ejca.2017.01.035 Miliotou, 2018, CAR T-cell therapy: a new era in cancer immunotherapy, Curr Pharm Biotechnol, 19, 5, 10.2174/1389201019666180418095526 O’Donnell, 2019, Cancer immunoediting and resistance to T cell-based immunotherapy, Nat Rev Clin Oncol, 16, 151, 10.1038/s41571-018-0142-8 Pitt, 2016, Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors, Immunity, 44, 1255, 10.1016/j.immuni.2016.06.001 Haibe, 2020, Resisting resistance to immune checkpoint therapy: a systematic review, Int J Mol Sci, 21, 10.3390/ijms21176176 Barrueto, 2020, Resistance to checkpoint inhibition in cancer immunotherapy, Transl Oncol, 13, 100738, 10.1016/j.tranon.2019.12.010 Abadjian, 2017, Imaging the tumor microenvironment, Adv Exp Med Biol, 1036, 229, 10.1007/978-3-319-67577-0_15 Shi, 2020, Metabolism in tumor microenvironment: Implications for cancer immunotherapy, MedComm, 1, 47, 10.1002/mco2.6 Lin, 2019, Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, Mol Cancer, 18, 139, 10.1186/s12943-019-1062-7 Frankel, 2017, The role of tumor microenvironment in cancer immunotherapy, Adv Exp Med Biol, 1036, 51, 10.1007/978-3-319-67577-0_4 Dougan, 2017, Targeting immunotherapy to the tumor microenvironment, J Cell Biochem, 118, 3049, 10.1002/jcb.26005 Bader, 2020, Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy, Mol Cell, 78, 1019, 10.1016/j.molcel.2020.05.034 Mimoto, 2020, Exploitation of elevated extracellular ATP to specifically direct antibody to tumor microenvironment, Cell Rep, 33, 108542, 10.1016/j.celrep.2020.108542 Di Virgilio, 2018, Extracellular ATP and P2 purinergic signalling in the tumour microenvironment, Nat Rev Cancer, 18, 601, 10.1038/s41568-018-0037-0 Boison, 2019, Adenosine metabolism: emerging concepts for cancer therapy, Cancer Cell, 36, 582, 10.1016/j.ccell.2019.10.007 Vigano, 2019, Targeting adenosine in cancer immunotherapy to enhance T-Cell function, Front Immunol, 10, 925, 10.3389/fimmu.2019.00925 Arab, 2019, Adenosine blockage in tumor microenvironment and improvement of cancer immunotherapy, Immune Netw, 19, 10.4110/in.2019.19.e23 Di Virgilio, 2017, The P2X7 receptor in infection and inflammation, Immunity, 47, 15, 10.1016/j.immuni.2017.06.020 Zumerle, 2019, Intercellular calcium signaling induced by ATP potentiates macrophage phagocytosis, Cell Rep, 27, 1, 10.1016/j.celrep.2019.03.011 Aymeric, 2010, Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity, Cancer Res, 70, 855, 10.1158/0008-5472.CAN-09-3566 MacKenzie, 2001, Rapid secretion of interleukin-1beta by microvesicle shedding, Immunity, 15, 825, 10.1016/S1074-7613(01)00229-1 Chen, 2006, ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors, Science, 314, 1792, 10.1126/science.1132559 Allard, 2020, The adenosine pathway in immuno-oncology, Nat Rev Clin Oncol, 17, 611, 10.1038/s41571-020-0382-2 Maliszewski, 1994, The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization, J Immunol, 153, 3574, 10.4049/jimmunol.153.8.3574 Canale, 2018, CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T cells, Cancer Res, 78, 115, 10.1158/0008-5472.CAN-16-2684 Leone, 2018, Targeting adenosine for cancer immunotherapy, J Immunother Cancer, 6, 57, 10.1186/s40425-018-0360-8 Sun, 2010, CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice, Gastroenterology, 139, 1030, 10.1053/j.gastro.2010.05.007 Tallón de Lara, 2021, CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer, Nat Commun, 12, 769, 10.1038/s41467-021-21045-2 Künzli, 2011, Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer, Purinergic Signal, 7, 231, 10.1007/s11302-011-9228-9 Gu, 2017, Human CD39(hi) regulatory T cells present stronger stability and function under inflammatory conditions, Cell Mol Immunol, 14, 521, 10.1038/cmi.2016.30 Álvarez-Sánchez, 2019, Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients, Sci Rep, 9, 2302, 10.1038/s41598-019-38897-w Zhao, 2017, What else can CD39 tell us?, Front Immunol, 8, 727, 10.3389/fimmu.2017.00727 Jackson, 2007, Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice, Am J Pathol, 171, 1395, 10.2353/ajpath.2007.070190 Häusler, 2014, Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion, Am J Transl Res, 6, 129 Hayes, 2015, CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma, Am J Transl Res, 7, 1181 Nikolova, M., et al., CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog, 2011. 7(7): p. e1002110. Perrot, 2019, Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies, Cell Rep, 27, 2411, 10.1016/j.celrep.2019.04.091 Zhang, 2019, The role of NK cells and CD39 in the immunological control of tumor metastases, Oncoimmunology, 8, e1593809, 10.1080/2162402X.2019.1593809 Feske, 2015, Ion channels in innate and adaptive immunity, Annu Rev Immunol, 33, 291, 10.1146/annurev-immunol-032414-112212 Plitas, 2016, Regulatory T cells: differentiation and function, Cancer Immunol Res, 4, 721, 10.1158/2326-6066.CIR-16-0193 Li, 2019, Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity, Cancer Discov, 9, 1754, 10.1158/2159-8290.CD-19-0541 Boyd-Tressler, 2014, Chemotherapeutic drugs induce ATP release via caspase-gated pannexin-1 channels and a caspase/pannexin-1-independent mechanism, J Biol Chem, 289, 27246, 10.1074/jbc.M114.590240